Annual Review of Cancer Biology最新文献_第3页

RAS and SHOC2 Roles in RAF Activation and Therapeutic Considerations RAS和SHOC2在RAF激活和治疗中的作用

Annual Review of Cancer Biology Pub Date : 2023-12-06 DOI: 10.1146/annurev-cancerbio-062822-030450

Daniel A. Bonsor, Dhirendra K. Simanshu

{"title":"RAS and SHOC2 Roles in RAF Activation and Therapeutic Considerations","authors":"Daniel A. Bonsor, Dhirendra K. Simanshu","doi":"10.1146/annurev-cancerbio-062822-030450","DOIUrl":"https://doi.org/10.1146/annurev-cancerbio-062822-030450","url":null,"abstract":"Mutations in RAS proteins play a pivotal role in the development of human cancers, driving persistent RAF activation and deregulating the mitogen-activated protein kinase (MAPK) signaling pathway. While progress has been made in targeting specific oncogenic RAS proteins, effective drug-based therapies for most RAS mutations remain limited. Recent investigations into RAS–RAF complexes and the SHOC2–MRAS–PP1C holoenzyme complex have provided crucial insights into the structural and functional aspects of RAF activation within the MAPK signaling pathway. Moreover, these studies have also unveiled new blueprints for developing inhibitors, allowing us to think beyond the current RAS and MEK inhibitors. In this review, we explore the roles of RAS and SHOC2 in activating RAF and discuss potential therapeutic strategies to target these proteins. A comprehensive understanding of the molecular interactions involved in RAF activation and their therapeutic implications can potentially drive innovative approaches in combating RAS-/RAF-driven cancers.Expected final online publication date for the Annual Review of Cancer Biology, Volume 8 is April 2024. Please see http://www.annualreviews.org/page/journal/pubdates for revised estimates.","PeriodicalId":501431,"journal":{"name":"Annual Review of Cancer Biology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-12-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138534799","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Deciphering the Warburg Effect: Metabolic Reprogramming, Epigenetic Remodeling, and Cell Dedifferentiation 解读Warburg效应:代谢重编程、表观遗传重塑和细胞去分化

Annual Review of Cancer Biology Pub Date : 2023-12-06 DOI: 10.1146/annurev-cancerbio-062822-120857

Albert M. Li, Jiangbin Ye

{"title":"Deciphering the Warburg Effect: Metabolic Reprogramming, Epigenetic Remodeling, and Cell Dedifferentiation","authors":"Albert M. Li, Jiangbin Ye","doi":"10.1146/annurev-cancerbio-062822-120857","DOIUrl":"https://doi.org/10.1146/annurev-cancerbio-062822-120857","url":null,"abstract":"A century ago, Otto Heinrich Warburg made a seminal discovery now known as the Warburg effect. This metabolic signature, prevalent across all cancer cells, is characterized by the prominent shift of glucose metabolism toward lactate production instead of oxidative respiration. Warburg's pioneering theory suggested that the induction of the Warburg effect instigates dedifferentiation and the process of tumorigenesis, illuminating a fundamental mechanism underlying cancer development. To celebrate the centennial anniversary of Warburg's monumental finding, it is an appropriate moment to reflect upon and commemorate his revolutionary contributions to the fields of metabolism and cancer research. In this review, we explore the role of mitochondria in epigenetic regulation and the decisions governing cell fate from an evolutionary standpoint. Moreover, we summarize metabolic and genetic factors that trigger the Warburg effect, underscoring the therapeutic potential of mitochondrial uncoupling as a strategy to counter this metabolic aberration. Our goal is to elucidate the means to induce tumor differentiation through metabolic therapy, thereby laying a foundation toward the cure for cancer.Expected final online publication date for the Annual Review of Cancer Biology, Volume 8 is April 2024. Please see http://www.annualreviews.org/page/journal/pubdates for revised estimates.","PeriodicalId":501431,"journal":{"name":"Annual Review of Cancer Biology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-12-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138534863","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Complex Roles of PTPN11/SHP2 in Carcinogenesis and Prospect of Targeting SHP2 in Cancer Therapy PTPN11/SHP2 在癌症发生过程中的复杂作用以及靶向 SHP2 治疗癌症的前景

Annual Review of Cancer Biology Pub Date : 2023-12-06 DOI: 10.1146/annurev-cancerbio-062722-013740

Alexander Scheiter, Li-Chun Lu, Lilian H. Gao, Gen-Sheng Feng

{"title":"Complex Roles of PTPN11/SHP2 in Carcinogenesis and Prospect of Targeting SHP2 in Cancer Therapy","authors":"Alexander Scheiter, Li-Chun Lu, Lilian H. Gao, Gen-Sheng Feng","doi":"10.1146/annurev-cancerbio-062722-013740","DOIUrl":"https://doi.org/10.1146/annurev-cancerbio-062722-013740","url":null,"abstract":"The nonreceptor tyrosine phosphatase SHP2 has been at the center of cell signaling research for three decades. SHP2 is required to fully activate the RTK/RAS/ERK signaling cascade, although the underlying mechanisms are not completely understood. PTPN11 , which encodes SHP2, is the first identified proto-oncogene that encodes a tyrosine phosphatase, with dominantly activating mutations detected in leukemias and solid tumors. However, SHP2 has pro- and antioncogenic effects, and the most recent data reveal opposite activities of SHP2 in tumor cells and microenvironment cells. Allosteric SHP2 inhibitors show promising antitumor effects and overcome resistance to inhibitors of RAS/ERK signaling in animal models. Many clinical trials with orally bioactive SHP2 inhibitors, alone or combined with other regimens, are ongoing for a variety of cancers worldwide, with therapeutic outcomes yet unknown. This review discusses the multifaceted functions of SHP2 in oncogenesis, preclinical studies, and clinical trials with SHP2 inhibitors in oncological treatment.Expected final online publication date for the Annual Review of Cancer Biology, Volume 8 is April 2024. Please see http://www.annualreviews.org/page/journal/pubdates for revised estimates.","PeriodicalId":501431,"journal":{"name":"Annual Review of Cancer Biology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-12-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138548485","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Central Role of the Antigen-Presentation and Interferon-γ Pathways in Resistance to Immune Checkpoint Blockade 抗原呈递和干扰素γ途径在免疫检查点阻断抵抗中的核心作用

Annual Review of Cancer Biology Pub Date : 2022-04-11 DOI: 10.1146/annurev-cancerbio-070220-111016

Annette Paschen, Ignacio Melero, Antoni Ribas

{"title":"Central Role of the Antigen-Presentation and Interferon-γ Pathways in Resistance to Immune Checkpoint Blockade","authors":"Annette Paschen, Ignacio Melero, Antoni Ribas","doi":"10.1146/annurev-cancerbio-070220-111016","DOIUrl":"https://doi.org/10.1146/annurev-cancerbio-070220-111016","url":null,"abstract":"<p>Resistance to immunotherapy is due in some instances to the acquired stealth mechanisms of tumor cells that lose expression of MHC class I antigen–presenting molecules or downregulate their class I antigen–presentation pathways. Most dramatically, biallelic β2-microglobulin (B2M) loss leads to complete loss of MHC class I expression and to invisibility to CD8<sup>+</sup> T cells. MHC class I expression and antigen presentation are potently upregulated by interferon-γ (IFNγ) in a manner that depends on IFNγ receptor (IFNGR) signaling via JAK1 and JAK2. Mutations in these molecules lead to IFNγ unresponsiveness and mediate loss of recognition and killing by cytotoxic T lymphocytes. Loss of MHC class I augments sensitivity of tumor cells to be killed by natural killer (NK) lymphocytes, and this mechanism could be exploited to revert resistance, for instance, with interleukin-2 (IL-2)-based agents. Moreover, in some experimental models,potent local type I interferon responses, such as those following intratumoral injection of Toll-like receptor 9 (TLR9) or TLR3 agonists, revert resistance due to mutations of JAKs.","PeriodicalId":501431,"journal":{"name":"Annual Review of Cancer Biology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138534862","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cancer Genomic Rearrangements and Copy Number Alterations from Errors in Cell Division 癌症基因组重排和细胞分裂错误引起的拷贝数改变

Annual Review of Cancer Biology Pub Date : 2022-01-18 DOI: 10.1146/annurev-cancerbio-070620-094029

Cheng-Zhong Zhang, David Pellman

引用次数: 0

Caught in a Web: Emerging Roles of Neutrophil Extracellular Traps in Cancer 陷入网络:中性粒细胞细胞外陷阱在癌症中的新角色

Annual Review of Cancer Biology Pub Date : 2022-01-18 DOI: 10.1146/annurev-cancerbio-080421-015537

Xue-Yan He, David Ng, Mikala Egeblad

引用次数: 0

RB1, Cancer Lineage Plasticity, and Therapeutic Resistance RB1，肿瘤谱系可塑性和治疗耐药性

Annual Review of Cancer Biology Pub Date : 2022-01-18 DOI: 10.1146/annurev-cancerbio-070120-092840

Letian Zhang, David W. Goodrich

引用次数: 0